cbdMD Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for cbdMD in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" cbdMD stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YCBD, but not buy additional shares or sell existing shares.
View analyst ratings for cbdMD or view top-rated stocks.

Wall Street analysts have given cbdMD a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but cbdMD wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

cbdMD saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 8,300 shares, a drop of 99.5% from the June 15th total of 1,660,000 shares. Based on an average daily trading volume, of 281,500 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are short sold.
View cbdMD's Short Interest.

cbdMD is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for cbdMD.

cbdMD, Inc. (NYSEAMERICAN:YCBD) announced its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.24) EPS for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.21. The business earned $11.80 million during the quarter. cbdMD had a negative trailing twelve-month return on equity of 35.34% and a negative net margin of 79.89%.
View cbdMD's earnings history.

cbdMD's stock was trading at $0.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, YCBD shares have increased by 195.1% and is now trading at $2.42.
View which stocks have been most impacted by COVID-19.

cbdMD issued an update on its first quarter 2022 earnings guidance on Tuesday, June, 8th. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $15.50 million-16.25 million.

2 analysts have issued twelve-month price objectives for cbdMD's stock. Their forecasts range from $3.25 to $4.00. On average, they anticipate cbdMD's share price to reach $3.63 in the next twelve months. This suggests a possible upside of 49.8% from the stock's current price.
View analysts' price targets for cbdMD or view top-rated stocks among Wall Street analysts.

Some companies that are related to cbdMD include United-Guardian (UG), CCA Industries (CAWW), Global Digital Solutions (GDSI), The Stephan (SPCO), FOMO (ETFM), NuGene International (NUGN), Ascendia Brands (ASCBQ), DS Healthcare Group (DSKX), Human Pheromone Sciences (EROX), Lee Pharmaceuticals (LPHM) and Nextera Enterprises (NXRA).
View all of YCBD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other cbdMD investors own include KushCo (KSHB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Novan (NOVN), Bionano Genomics (BNGO), Cannabics Pharmaceuticals (CNBX), Enerplus (ERF), Matinas BioPharma (MTNB), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

cbdMD trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "YCBD."

cbdMD's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Davy Global Fund Management Ltd (0.38%) and Cutler Group LP (0.00%). Company insiders that own cbdMD stock include Bakari T Sellers, Mark S Elliott, Martin A Sumichrast, Peter J Ghiloni, Raymond Scott Coffman and William F Raines III.
View institutional ownership trends for cbdMD.

YCBD stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold cbdMD company stock in the last year include Bakari T Sellers, Martin A Sumichrast, Raymond Scott Coffman, and William F Raines III.
View insider buying and selling activity for cbdMD or view top insider-selling stocks.

YCBD stock was acquired by a variety of institutional investors in the last quarter, including Davy Global Fund Management Ltd. Company insiders that have bought cbdMD stock in the last two years include Bakari T Sellers, Mark S Elliott, Peter J Ghiloni, and Raymond Scott Coffman.
View insider buying and selling activity for cbdMD or or view top insider-buying stocks.

Shares of YCBD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of YCBD stock can currently be purchased for approximately $2.42.

cbdMD has a market capitalization of $136.54 million and generates $41.88 million in revenue each year. The company earns $12.60 million in net income (profit) each year or $0.28 on an earnings per share basis.

cbdMD employs 165 workers across the globe.

The official website for cbdMD is www.cbdmd.com.

cbdMD is headquartered at 8845 Red Oak Boulevard, Charlotte NC, 28217.

cbdMD's mailing address is 8845 Red Oak Boulevard, Charlotte NC, 28217. The company can be reached via phone at 704-445-5800 or via email at [email protected]